Albireo Pharma, Inc Earning Date (ALBO)

USA |NASDAQ |USD

ALBO Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-1.90
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $2.43M

Albireo Pharma, Inc's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

ALBO Earnings Date & History Chart

ALBO Earnings & Revenue Forecast

ALBO Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 7 $-6.37 $-8.00 $-4.88

ALBO Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-6.52 $-6.31 $-6.05

ALBO Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 7 $52.70M $31.00M $62.50M

ALBO Earnings Date & Revenue History

ALBO Earnings History

|
Show More
Show More

ALBO Revenue History

|
Show More
Show More

Albireo Pharma, Inc Next Earnings Date & Report

ALBO Next Earnings Date & Report Preview: Jun 2022 (FQ)

ALBO's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Albireo Pharma, Inc Previous Earnings Dates & Reports

ALBO Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Albireo Pharma, Inc's previous earnings date was May 4, 2022 for its fiscal quarter ended Mar 31, 2022.

ALBO Previous Earnings Date & Report Recap: Dec 2021 (FY)

Albireo Pharma, Inc's previous annual earnings date was Mar 1, 2022 for its fiscal year ended Dec 31, 2021.

ALBO's earnings per share (EPS) was $-6.83, missing the consensus analysts forecast of $-3.64 by 87.64% , and higher than the previous year's EPS (Dec 2020) by -0.58%.

Revenues were $40.58M, better than the forecast of $13.24M by 206.49%, and up by 388.43% from previous year's revenue.

The company reported a net income of $-34.03M.

Albireo Pharma, Inc reported a free cash flow of $-108.02M for its fiscal year, compared to $-101.11M a year ago.